Oxford University has said there are no safety concerns over the vaccine but that it will wait for data on blood clotting before resuming trials.
The University of Oxford said it will pause trials of the AstraZeneca vaccine in children and teenagers as it awaits guidance from the European Medicines Agency (EMA) on a small number of cases of blood clotting. The MHRA reported that there had been 30 blood clotting cases, seven fatal, out of the 18 million doses administered in the UK.
The European Medical Agency (EMA) is currently investigating reports of a rare brain blood clot known as cerebral venous sinus thrombosis (CVST) after the administration of the vaccine. The condition is not listed as a possible side-effect of this vaccine.
Many countries have halted the use of the vaccine as a precautionary measure after similar reports of blood clots.
The EMA is expected to confirm if there is any link between the vaccine and blood clots. The University has said though there are no safety concerns over AstraZeneca but that it will wait until further data is available.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.